SCHEMBL589119

SCHEMBL589119

Nc1nc(Cl)c(Br)nc1Cl

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.32
KDM4E B2RXH2 3/20 0.32
GLA P06280 3/20 0.32
HPGD P15428 3/20 0.32
HSD17B10 Q99714 3/20 0.32
LMNA P02545 2/20 0.32
GAA P10253 2/20 0.32
PLAU P00749 2/20 0.32
CYP1A2 P05177 2/20 0.32
SLC22A1 O15245 1/20 0.32
HTR1A P08908 1/20 0.32
CYP2D6 P10635 1/20 0.32
TSHR P16473 1/20 0.32
SLC9A1 P19634 1/20 0.32
MAOA P21397 1/20 0.32
ADORA2A P29274 1/20 0.32
CYP2C19 P33261 1/20 0.32
ADRA1A P35348 1/20 0.32
OPRM1 P35372 1/20 0.32
SCNN1A P37088 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31471091 0.83 PLAU (0.32) ALDH1A1PLAUKMT2A
SCHEMBL362613 0.83 PLAU (0.32) ALDH1A1PLAUKMT2A
SCHEMBL29209630 0.82 ALDH1A1 (0.33) ALDH1A1TSHR
SCHEMBL11837238 0.82 ALDH1A1 (0.39) ALDH1A1KDM4EGLAHPGDHSD17B10
SCHEMBL20799620 0.80 PLAU (0.33) ALDH1A1PLAUKMT2A
SCHEMBL31289724 0.77 LMNA (0.39) ALDH1A1LMNAHTTKMT2A
SCHEMBL29209568 0.76 TDP1 (0.32) TDP1
SCHEMBL30881607 0.76 TDP1 (0.32) TDP1
SCHEMBL30519316 0.76
SCHEMBL1732884 0.76 ALDH1A1 (0.37) ALDH1A1KDM4EGLAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3700578-B1 SYSTEMS FOR RENAL FUNCTION DETERMINATION MEDIBEACON INC (US) 2025-12-03 EP disclosed
US-12303570-B2 Compositions and methods for assessing eye vasculature MEDIBEACON INC. (US) 2025-05-20 US disclosed
US-20230173111-A1 COMPOSITIONS AND SYSTEMS FOR RENAL FUNCTION DETERMINATION MEDIBEACON INC. 2023-06-08 US disclosed
US-20230173111-A1 COMPOSITIONS AND SYSTEMS FOR RENAL FUNCTION DETERMINATION MEDIBEACON INC. 2023-06-08 US disclosed
US-20230173111-A1 COMPOSITIONS AND SYSTEMS FOR RENAL FUNCTION DETERMINATION MEDIBEACON INC. 2023-06-08 US disclosed
US-20230158175-A1 METHODS FOR RENAL FUNCTION DETERMINATION MEDIBEACON INC. 2023-05-25 US disclosed
US-20230158175-A1 METHODS FOR RENAL FUNCTION DETERMINATION MEDIBEACON INC. 2023-05-25 US disclosed
US-20230158175-A1 METHODS FOR RENAL FUNCTION DETERMINATION MEDIBEACON INC. 2023-05-25 US disclosed
US-20230132384-A9 COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE MEDIBEACON INC. 2023-04-27 US disclosed
US-20230132384-A9 COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE MEDIBEACON INC. 2023-04-27 US disclosed
US-20090198053-A1 Pyrazine Derivatives and Uses Thereof in Renal Monitoring MEDIBEACON INC. 2009-08-06 US disclosed
US-20090198053-A1 Pyrazine Derivatives and Uses Thereof in Renal Monitoring MEDIBEACON INC. 2009-08-06 US disclosed
US-20090198053-A1 Pyrazine Derivatives and Uses Thereof in Renal Monitoring MEDIBEACON INC. 2009-08-06 US disclosed
CN-101472903-A Pyrazine derivatives with extended conjugation and uses thereof MALLINCKRODT INC (US) 2009-07-01 CN disclosed
EP-2038261-A2 PYRAZINE DERIVATIVES WITH EXTENDED CONJUGATION AND USES THEREOF Mallinckrodt Inc. (US) 2009-03-25 EP disclosed
EP-2029554-A1 PYRAZINE DERIVATIVES AND USES THEREOF IN RENAL MONITORING Mallinckrodt, Inc. (US) 2009-03-04 EP disclosed
CN-101351454-A Pyrazine derivatives and their use in renal monitoring MALLINCKRODT INC (US) 2009-01-21 CN disclosed
WO-2007149478-A2 PYRAZINE DERIVATIVES WITH EXTENDED CONJUGATION AND USES THEREOF MALLINCKRODT INC. (US) 2007-12-27 WO disclosed
WO-2007149479-A1 PYRAZINE DERIVATIVES AND USES THEREOF IN RENAL MONITORING MALLINCKRODT INC. (US) 2007-12-27 WO disclosed
WO-2007149479-A1 PYRAZINE DERIVATIVES AND USES THEREOF IN RENAL MONITORING MALLINCKRODT INC. (US) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230132384-A9 COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE LIPG, FLT4, FABP3 ALDH1A1 1933/4885KDM4E 4110/4885GLA 231/4885
US-20230173111-A1 COMPOSITIONS AND SYSTEMS FOR RENAL FUNCTION DETERMINATION GLS, ATP6V1B1, REN ALDH1A1 3528/4885KDM4E 4756/4885GLA 873/4885
US-20090198053-A1 Pyrazine Derivatives and Uses Thereof in Renal Monitoring GLS, CYP3A5, PYCR1 ALDH1A1 268/4885KDM4E 2058/4885GLA 3357/4885
US-20230158175-A1 METHODS FOR RENAL FUNCTION DETERMINATION GLS, SHBG, OGFR ALDH1A1 1776/4885KDM4E 4201/4885GLA 347/4885
US-12303570-B2 Compositions and methods for assessing eye vasculature LIPG, FLT4, FABP3 ALDH1A1 1933/4885KDM4E 4110/4885GLA 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.